ASXL1 and myelodysplastic syndrome: Additionally, future studies should further elucidate the prognostic and therapeutic implications of genomic alterations commonly seen in pediatric MDS, including mutations in RAS pathway genes, RUNX1, SETBP1, and ASXL1, which differ significantly from those observed in adult populations.